Pharmacovigilance World 2021

Virtual Conference / Summit
Healthcare Pharmaceuticals

Date: 23 to 24 Nov '21
Time: 10:00am to 6:00pm (GMT) Greenwich Mean Time: Dublin, Edinburgh, Lisbon, London
Price: Under 250 GBP£

Visit Event Website


 OPTIMIZING PHARMACOVIGILANCE AND RISK MANAGEMENT STRATEGIES
TO AN EVOLVING DRUG SAFETY ENVIRONMENT


With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug. However, evidences suggest though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk.

In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use.  Pharmacovigilance brief the potential implications of such trends on the evolution of the science. 

However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc. 
 
The Pharmacovigilance World 2021 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and contribute to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field. Our Pharmacovigilance conferences are known for bringing the world-class leaders together to connect, learn and network. The conference will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.
 
It gives us a great pleasure in welcoming you to the Pharmacovigilance World 2021 conference.

KEY HIGHLIGHTS

  • Pharmacovigilance and globalization
  • Pharmacovigilance in a pandemic world
  • Women and child health care medicines and pharmacovigilance
  • Patient-centric approaches in PV
  • Pharmacovigilance legislation and regulations
  • Harmonization and pharmacovigilance
  • Advanced therapeutic techniques and pharmacovigilance
  • Pharmacovigilance and data management and eudravigilance
  • Post-marketing surveillance in pharmacovigilance
  • PV regulations and challenges
  • Benefit-risk management strategies
  • Risk management and minimization
  • Adverse drug reactions reporting
  • Signal detection and post authorization safety
  • Good Pharmacovigilance Practices
  • Innovative approaches to drug safety
  • Strategies to improve PV
  • Real World Evidence in PV
  • Big data and AI in pharmacovigilance
  • Pharmacovigilance Monitoring and automation in Social media
  • Other emerging technologies in PV
 

WHO SHOULD ATTEND PHARMACOVIGILANCE 2021
 
CEOs, CTOs, CIOs, Presidents, Vice Presidents, Directors, Heads & Managers, Scientific Advisors, Consultants and professionals who work for pharmaceutical, biotechnology & devices industries, CROs and service providers involved in Pharmacovigilance and Drug safety.

Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of:

  • Pharmacovigilance
  • Safety & Risk management
  • Drug safety
  • PV Compliance
  • Safety Surveillance
  • Medical Affairs
  • Regulatory Affairs
  • Inspection and Audit
  • Pharmacoepidemiology
  • Post-market studies
  • Medical product safety assessment
  • Drug Research & Development
  • Clinical Pharmacology
  • Medical information
  • Contract outsourcing service providers
  • Health outcomes
  • Sales and Marketing

Allison Stogdale

Associate Director, Global Patient Safety & Risk Management
Alnylam Pharmaceuticals

Andreas Osanger

Director - Therapeutic Area Lead Nephrology - Vifor Pharma

Dawn Mucci

Team Lead, Patient Safety Compliance and Enablement
AstraZeneca

Dimitris Zampatis

Scientific Director, Safety Strategy Lead
Healthcare Business of Merck

Enrico Santus

Data Science Leader in Pharmacovigilance - Bayer

Isabelle Lalande-Luesink

Global Head Operational Excellence - Novartis Pharmaceuticals

Joan Francesc Aregall Picamal

Pharmacovigilance Country Head, Spain
Bayer

JULIE GIROD

Associate Vice President, Global Head of Case Management and Medical Evaluation
Sanofi

Kate Gofman

Global Safety Physician, AI & Blockchain Innovator - AstraZeneca

Khaudeja Bano

Head of Combination Product and Device Safety, Executive Medical Director
Amgen

Kishan Nandha

PVQA Manager & Lead Auditor - Astellas Pharma US

Lisa Stagi

Drug Safety & Quality Head - Roche

Mayada Alkhakany

Senior Global NTA( non-trial activities) Manager - Boehringer Ingelheim

Raghda Mohamed

Patient Safety Cluster Lead - Middle East and Turkey / Global patient Safety Evaluation
Takeda

Rama Diop

Head Patient Safety Region Africa - Novartis

Raphael Elmadjian Pareschi

Associate Director Pharmacovigilance - MSD

Rodrigo Ruiz

Head of Country Pharmacovigilance Mexico
Bristol-Myers Squibb

Ryan Kilpatrick

Head, Global Epidemiology - Abbvie

Stephanie Tcherny

Global Head of Benefit-Risk Evaluation
Sanofi

Tea Babić

Director, PV Audits and Inspections
Teva Pharmaceuticals

Valentina Mancini

Director Pharmacovigilance, EU and UK QPPV
Shionogi Europe

Victoria Abdala

ROPU South America Pharmacovigilance Head
Boehringer Ingelheim

WIVINA DE WAELE

Director EMEA, Global Drug Safety
Alexion Pharmaceuticals, Inc

Yvonne Nanciu

Country Head Pharmacovigilance Germany
Bayer Pharmaceuticals

Allison Stogdale

Associate Director, Global Patient Safety & Risk Management
Alnylam Pharmaceuticals

Andreas Osanger

Director - Therapeutic Area Lead Nephrology - Vifor Pharma

Dawn Mucci

Team Lead, Patient Safety Compliance and Enablement
AstraZeneca

Dimitris Zampatis

Scientific Director, Safety Strategy Lead
Healthcare Business of Merck

Enrico Santus

Data Science Leader in Pharmacovigilance - Bayer

Isabelle Lalande-Luesink

Global Head Operational Excellence - Novartis Pharmaceuticals

Joan Francesc Aregall Picamal

Pharmacovigilance Country Head, Spain
Bayer

JULIE GIROD

Associate Vice President, Global Head of Case Management and Medical Evaluation
Sanofi

Kate Gofman

Global Safety Physician, AI & Blockchain Innovator - AstraZeneca

Khaudeja Bano

Head of Combination Product and Device Safety, Executive Medical Director
Amgen

Kishan Nandha

PVQA Manager & Lead Auditor - Astellas Pharma US

Lisa Stagi

Drug Safety & Quality Head - Roche

Mayada Alkhakany

Senior Global NTA( non-trial activities) Manager - Boehringer Ingelheim

Raghda Mohamed

Patient Safety Cluster Lead - Middle East and Turkey / Global patient Safety Evaluation
Takeda

Rama Diop

Head Patient Safety Region Africa - Novartis

Raphael Elmadjian Pareschi

Associate Director Pharmacovigilance - MSD

Rodrigo Ruiz

Head of Country Pharmacovigilance Mexico
Bristol-Myers Squibb

Ryan Kilpatrick

Head, Global Epidemiology - Abbvie

Stephanie Tcherny

Global Head of Benefit-Risk Evaluation
Sanofi

Tea Babić

Director, PV Audits and Inspections
Teva Pharmaceuticals

Valentina Mancini

Director Pharmacovigilance, EU and UK QPPV
Shionogi Europe

Victoria Abdala

ROPU South America Pharmacovigilance Head
Boehringer Ingelheim

WIVINA DE WAELE

Director EMEA, Global Drug Safety
Alexion Pharmaceuticals, Inc

Yvonne Nanciu

Country Head Pharmacovigilance Germany
Bayer Pharmaceuticals

Stay Updated

Organizer

Corvus Global Events

Stay Updated

Organizer

Corvus Global Events

Copyright © 2021 Industry Events. All rights reserved. Site credit.